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Abstract
A cDNA encoding the rat m-opioid receptor was expressed stably in a Rat-1 fibroblast cell line. Expression of this
w3 xw xreceptor was demonstrated with specific binding of the m-opioid selective ligand H D-Ala2,N-MePhe4,Gly5-ol -enkepha-
w3 x .lin H DAMGO . In membranes of clone m11 cells DAMGO produced a robust, concentration-dependent stimulation of
w32 xbasal high affinity GTPase activity. Cholera toxin-catalyzed P ADP-ribosylation in membranes of this clone labelled a
 .40 kDa G family polypeptide s that was markedly enhanced by the addition of DAMGO. Antisera against G 2a and G 3ai i i
w32 x  .were both able to immunoprecipitate a P -radiolabelled 40 kDa polypeptide s from DAMGO and cholera-toxin treated
membranes of clone m11, indicating that the m-opioid receptor was able to interact effectively with both G 2 and G 3 ini i
Rat-1 fibroblasts. A series of peptides derived from the d-opioid receptor sequence were assessed for their ability to modify
w3 xagonist-stimulated G protein activation and H agonist binding to the receptor. In membranes from the clone m11, specific
w3 xbinding of H DAMGO was reduced by peptides corresponding to the NH -terminal region of the third intracellular loop2
 .  .i3.1 and the carboxyl-terminal tail i4 of this receptor. Agonist stimulated GTPase activity and DAMGO dependent
w32 x  .cholera toxin-catalyzed P ADP-ribosylation were inhibited by peptides derived from the proximal i3.1 and the distal
 . w35 x X  .portion i3.3 of the third intracellular loop. Peptide i3.1 also inhibited DAMGO-stimulated S guanosine-5 -O- 3-thio tri-
w35 x .phosphate S GTPgS binding in the same membranes. In contrast, peptides derived from the second intracellular loop
were without any effect. q 1997 Elsevier Science B.V.
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1. Introduction
All of the identified opioid receptors share similar
structural characteristics comprising an integral mem-
brane protein composed of seven hydrophobic trans-
membrane spanning helices which are connected by
alternating extracellular and intracellular hydrophobic
loops. The m, d, and k subtypes of opioid receptors
have recently been cloned. The cytoplasmic hy-
drophillic domains of the three cloned opioid recep-
tors reveal high sequence similarity, especially in the
second and the third intracellular loops which have
about 90% amino acid identity, indicating that these
w xreceptors might interact with similar G proteins 1–3 .
Functional analysis of a considerable number of G
 .protein-coupled receptors GPCRs has shown that a
given receptor subtype, although displaying a degree
of promiscuity, interacts with high affinity only with
distinct subsets of G proteins. The opioid receptors
are classically described as coupling to members of
w xthe G arG a family 4–6 and agonist occupancy ofi 0
the receptors has been reported to result in the inhibi-
tion of adenylate cyclase andror the regulation of ion
w xchannels 4,7,8 . Reconstitution experiments using G
proteins and m-opioid receptors purified by an affin-
ity chromatography have indicated the potential for
interaction of this receptor type with both G or Gi 0
w xfamilies of G proteins 5 , whereas in NG108-15
hybrid cells, the d-opioid receptor appears to activate
w x w xG 2, 9 G and possibly G 3 10,11 .i 0 i
Using selective G protein antisera, both in native
and solubilised rat brain membranes, we have previ-
ously demonstrated that both the C- and N-terminal
regions of G a play a key role in opioid receptor–G0 0
w xprotein interactions 6,11 . However the question of
 .which heterotrimeric G-protein s is involved in a
specific opioid function and which sites on the recep-
tor possess determinants for G protein coupling re-
mains still unclear. Therefore, expression of these
receptor species in heterologous cell systems would
allow a more detailed examination of their signalling
characteristics.
Little is understood about the secondary structure
of the intracellular domains of GPCRs known to be
involved in G protein coupling. Such knowledge lies
at the heart of unravelling the molecular mechanisms
governing the specificity of GPCR–G protein interac-
w xtions. Using chimeric receptors 12,13 , site directed
w x w xmutagenesis 14,15 , and peptide studies 16–18 sev-
eral laboratories have tried to delineate regions of the
primary structure of GPCRs which might define a
consensus domain for effective G protein coupling.
These studies suggest that there is variation between
different GPCR families.
Using synthetic peptides based on the predicted
sequence of the d-opioid receptor to study the intra-
cellular receptor domains of this receptor subtype, we
have recently provided evidence that the third intra-
cellular loop and part of the C-terminal tail of this
receptor are critical for functional G-protein coupling
w x19 . The third intracellular loop of the d-opioid
receptor is comprised of some 25 amino acids. These
are identical in the m-opioid receptor with the excep-
tion of amino acids Leu237, Arg241, Leu245, and
 .Ser255 in the d-opioid receptor which are replaced
with Ile256, Lys260, Met264 and Asn274 in the
m-opioid receptor. On the other hand, although the
carboxyl-terminal tail shows a high degree of amino
acid diversity, it contains a conserved domain which
is shared between the d- and m-opioid receptors with
the only exceptions being amino acids Gln331 and
Leu332 of the d-opioid receptor which are replaced
by Glu349 and Phe350 in the m-opioid receptor.
Based on these similarities in the primary amino
acid sequence amongst the intracellular regions of
these receptors, we suspected that the same sites
might also be responsible for effective G protein
coupling for the m-opioid receptor. Therefore we
have measured the ability of various receptor derived
peptides to modify ligand stimulated G protein acti-
w3 xvation and H agonist binding. In order to achieve
this a cDNA encoding the rat m-opioid receptor was
expressed stably in Rat-1 fibroblasts which do not
express endogenously any opioid receptors. Taking
advantage of the ability of cholera toxin to catalyze
w32 xP ADP-ribosylation of pertussis toxin-sensitive G
proteins after they have been activated, we initially
demonstrate that the m-opioid receptor can function-
ally interact with both G 2a and G 3a when ex-i i
pressed in this genetic background. Moreover, using
membranes from this cell line, we demonstrate for
the first time, the involvement of the third intra-
cellular loop and the proximal part of the C-terminal
tail of the m-receptor as the key structural determi-
nants responsible for effective G protein coupling to
this GPCR.
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2. Materials and methods
2.1. Generation and isolation of clones of Rat-1
fibroblasts expressing the rat m-opioid receptor
Clone m11 cells were obtained through transfec-
tion of Rat-1 fibroblasts with the use of lipofectin
 .reagent Life Technologies, Grand Island, NY with a
cDNA encoding the rat m-opioid receptor in the
mammalian expression vector pRCrCMV. Clones
were selected based on their resistance to geneticin
 .sulphate 700 mgrml , expanded and the specific
w3 xbinding of the H opioid agonist was subsequently
determined. The cDNAs encoding the rat m-opioid
receptor were kindly provided by Drs G. Uhl, Balti-
more, MD, and L. Yu, Bloomington, IN.
2.2. Cell culture
Cells of clone m11 were grown in Dulbecco’s
Modified Eagle’s Medium supplemented with 5%
 .newborn calf serum, penicillin 100 Urml and
 .streptomycin 100 mgrml in 5% CO at 378C.2
Membranes from these cells were prepared by ho-
mogenization as described for a variety of other cells
w x20 .
2.3. Peptide synthesis
Peptides were synthesized with an Applied Biosys-
 .tems Peptide Synthesizer model 430A, Norwalk,CT
w xas described in 19 . Peptides from the second, third
intracellular loops and the proximal part of the C-
terminal tail of the murine d-opioid receptor were
 .generated from the indicated regions Fig. 1 of the
w xpublished sequence 1,2,19 . These were designated
i2.1, residues 144–153; i2.2, residues 154–165; i3.1,
236–248; i3.2, 248–256; i3.3, 256–264, and i4,
 .322–333 residues Fig. 1 .
2.4. Binding experiments
In experiments designed to define ligand speci-
 .ficity, m11 membranes 15mg in 20 mM TrisrHCl
 . pH 7.5 , 20 mM MgCl and 50 mM sucrose buffer2
. w3 xA were incubated at 308C for 45 min with H dipre-
 . w3 x  .norphine 0.1–15 nM or H DAMGO 0.2–20 nM .
Non-specific binding was defined with the use of
parallel tubes containing 10 mM naloxone. In experi-
ments in which uncoupling of opioid receptors from
G proteins was performed, the membranes were
 .preincubated with different peptides 100 mM , as
 .  .described in Fig. 1; Gpp NH p 100 mM ; or buffer
for 60 min at 308C before the addition of ligands.
Binding was terminated by rapid filtration through
Whatman GFrC filters, followed by extensive washes
with ice-cold buffer A. Filters were maintained
overnight in Aquasol before liquid scintillation count-
ing. Analysis of the binding data were performed
with the computer program EBDA Biosoft, Mill-
. w xtown, NJ 21 .
Fig. 1. Alignment and amino acid composition of the m-opioid
 .receptor and the peptides used. Peptides i2.1 144–153 and i2.2
 .154–165 correspond to the NH - and COOH-terminal regions2
of the second intracellular loop, respectively. Peptides i3.1 236–
.  .248 and i3.3 256–264 correspond to the NH - and COOH-2
regions of the third intracellular loop respectively, and peptide
i3.2 to an intermediate part of the third intracellular loop. Peptide
 .i4 322–333 was derived from the cytoplasmic proximal car-
w xboxyl-terminal region of the d-opioid receptor 1–3,19 . In bold
type are indicated the amino acid differences between the pep-
tides and m-opioid receptor
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2.5. High affinity GTPase
GTPase activity in m11 cell membranes was deter-
w xmined as described previously 9 at 378C, using
w32 x  .g- P GTP 0.5 mM, 60,000 cpm . Low affinity
 .GTPase 5–10% of the total counts was assessed by
parallel assays containing 100 mM GTP and was
subtracted from the total activity to give the amount
of high affinity GTPase activity. Membranes in
10 mM TrisrHCl, pH 7.5, 0.1 mM EDTA and 5 mM
MgCl , were preincubated in the presence of the2
 .peptides 100 mM for 60 min at 308C before assess-
ment of DAMGO stimulated high affinity GTPase
activity.
[35 ]2.6. Binding of S GTPgS
 .GTPgS binding of the m11 cell membranes 15mg
 .was performed in a reaction mixture 100 ml contain-
 .ing 20 mM Hepes pH 7.4 , 100 mM NaCl, 10 mM
w35 xGDP, 0.2 mM ascorbate and 0.3–0.5 nM S GTPgS
 .50 nCi . Before assay, membranes in 10 mM
TrisrHCl pH 7.4, 0.1 mM EDTA were preincubated
in the presence of 3 mM MgCl and the presence of2
 .peptides 100 mM , or buffer for 1 h at 308C. The
reaction was initiated after the preincubation period
by the addition of the reaction mixture in the pres-
 .ence or absence of DAMGO 10 mM and the sam-
ples were incubated at 48C for 1 h. The reaction was
terminated by rapid filtration through GFrC What-
man filters, followed by extensive three times with
.4 ml washes with ice-cold washing buffer consisting
of 20 mM Hepes, pH 7.4, and 3 mM MgCl . Bound2
radioactivity was quantified by counting the filters in
an Aquasol scintillation cocktail. Non-specific bind-
ing was determined in the presence of 10 mM unla-
belled GTPgS and was subtracted from total bound
w35 xS GTPgS.
[32 ]2.7. Cholera toxin-catalyzed P ADP-ribosylation
w32 xP ADP-ribosylation of membranes of cells of
clone m11 was performed in the absence of added
w xguanine nucleotide as in 22,23 . In experiments in
which the presence of peptides was required, mem-
branes in 10 mM TrisrHCl, pH 7.5, 0.1 mM EDTA
and 5 mM MgCl were preincubated in the presence2
 .of peptides 100 mM or buffer for 60 min at 308C
before the initiation of ribosylation. Dried gels were
autoradiographed by using Kodak X-Omat X-ray film
or were exposed overnight to a phosphor storage
plate for 24 h and then analysed using a FUJIX
BAS1000 image analyser.
2.8. Immunoprecipitation studies
w32 xTo immunoprecipitate G proteins, P ADP-
ribosylated membranes were resuspended in 200 ml
 .of 1% wrv SDS and boiled for 4 min. Subsequently
w  .800 ml of ice-cold buffer B 1.25% wrv Triton
X-100, 190 mM NaCl, 6 mM EDTA, 50 mM Tris–
xHCl, pH 7.5 plus protease inhibitors was added as
w xdescribed in 24 . Non-solubilized material was re-
moved after an hour incubation at 48C by centrifuga-
tion at 14 000=g for 10 min. Immunoprecipitation
was achieved by addition of 10–20 ml of the relevant
antiserum and incubation for 12–16 h at 48C. Subse-
 .quently, 50 ml of Pansorbin Calbiochem was added
for further 3 h with constant mixing. Finally the
immune complexes were collected by centrifugation
 .14 000=g, 3 min, 48C . These pellets were washed
two times with 1 ml of mixture consisting of 4:1 of
 .buffer B and 1% wrv SDS, followed with 50 mM
TrisrHCl, pH 6.8. The immune complexes were
resuspended in Laemmli sample buffer and subjected
w  .xto SDSrPAGE 10% wrv acrylamide . Gels were
stained with Coomassie Blue, dried and then autora-
diographed using X-OMat X-ray film, or were ex-
posed to a phosphor storage plate and developed with
a FUJIX Image analyzer.
2.9. Statistical analysis
All data are expressed as the mean " standard
error of three or more individual experiments. Each
experiment was carried out in triplicate. Statistical
analysis was performed with one way analysis of
variance and Student’s t-test, with P-0.05 indicat-
ing significance.
2.10. Materials
w3 x  . w3 xH Diprenorphine 39 Cirmmol , H DAMGO
 . w 32 x  .60 Cirmmol , and g- P GTP 6000 Cirmmol
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w35 xwere purchased from Amersham. S GTPgS
 . w32 x1150 Cirmmol and P NAD were obtained from
Du PontrNew England Nuclear. Opioid ligands,
GTP, ATP, GppNHp, cholera toxin, geneticin and all
other reagents were of analytical grade from Sigma.
All reagents for tissue culture were from
GIBCOrBRL.
3. Results
3.1. Characterization of the receptor expressed in
Rat-1 fibroblasts transfected with the rat m-opioid
receptor cDNA
Stable expression of a construct of a cDNA encod-
ing the rat m-opioid receptor in the mammalian ex-
pression vector pRCrCMV was achieved by trans-
fecting this construct into Rat-1 fibroblasts using
lipofectin. Colonies resistant to geneticin sulphate
 .700 mgrml were selected and expanded. The spe-
w3 xcific binding of H diprenorphine was assessed in
membranes from a series of clones to screen for
 .opioid receptor expression. One clone m11 was
identified in this fashion as expressing satisfactory
levels of opioid receptor and was selected for detailed
analysis. Saturation analysis of the specific binding of
the highly selective m-opioid receptor agonist
w3 xH DAMGO to membranes of clone m11 indicated a
B of 1550"170 fmol of receptorrmg of mem-max
brane protein and a K for this ligand of 0.8"d
 .   ..0.05 nM mean"standard error, ns3 Fig. 2 A .
In addition, expression of mRNA encoding this re-
ceptor was also demonstrated by reverse transcrip-
 . tase-polymerase chain reaction RT-PCR data not
.shown . To investigate the interactions of the trans-
fected m-opioid receptor with the G proteins, we
measured the ability of this receptor to stimulate high
affinity GTPase activity in membranes prepared from
clone m11. Membranes derived from clone m11 dis-
played a basal high affinity GTPase activity of 16"
1.5 pmolrminrmg membrane protein when mea-
sured in the presence of 100 mM NaCl. This activity
was stimulated in a dose-dependent manner by the
m-opioid peptide DAMGO with an EC of 70"2 nM50
 .ns3 indicating productive coupling of the m-opioid
receptor with the cellular G protein population Fig.
 ..2 B . This stimulation was reversed by the opioid
antagonist naloxone and attenuated by pertussis toxin
 .pretreatment of m11 cell membranes data not shown .
 .Fig. 2. A Expression of the m-opioid receptor in Rat-1 fibrob-
last, clone m11. The specific binding of varying concentrations of
w3 x  .H DAMGO 0.2–20 nM was measured in membranes of clone
m11. Non-specific binding was assessed in the presence of 10 mM
naloxone as described in Section 2. In the example displayed
B was estimated to be 1550fmolrmg membrane protein withmax
w3 x  .a K for H DAMGO of 0.8 nM. B Concentration-dependentd
effect of DAMGO on GTPase activity in membranes of clone
 .m11. Membranes 5mg from clone m11 were incubated with
varying concentrations of DAMGO and the high affinity GTPase
activity was assessed as described in Section 2. Basal GTPase
 .activity was 16"1.5 pmolrminrmg mean"standard error . Re-
sults are from one representative experiment which was repeated
three times. The EC value for DAMGO was 70"2nM.50
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3.2. Ability of the m-opioid receptor expressed in
Rat-1 fibroblasts to interact specifically with G 2ai
and G 3ai
Under defined conditions thiol-activated cholera
toxin can be used to detect agonist activated G -likei
w32 xG proteins by its ability to catalyze P ADP-ribo-
sylation of their a subunits. Using a panel of antipep-
tide antisera directed against regions of the primary
amino acid sequences of the individual G protein a
subunits we have previously identified the endoge-
nously polypeptides present in Rat-1 fibroblasts
w x9,11,23 . In order to define the molecular identity of
the pertussis toxin sensitive G proteins which interact
with the m-opioid receptor, cholera toxin-catalyzed
w32 xP ADP-ribosylation was performed on membranes
from clone m11, in the absence of guanine nu-
cleotides and in the presence or absence of the m-
 .opioid agonist DAMGO 10 mM . Resolution of
membrane proteins by SDS–PAGE and subsequent
autoradiography following such treatment resulted in
w32 xthe incorporation of P ADP-ribose into both the
 .  .long 45 kDa and short 42 kDa isoforms of G as
 .Fig. 3 . However, there was also incorporation of
radioactivity into an apparently single 40 kDa
 .polypeptide s corresponding in mobility to G a . In-i
w32 xcorporation of P ADP-ribose into this 40 kDa
 .polypeptide s was markedly enhanced after the addi-
tion of 10 mM DAMGO, whereas labelling of both
splice variants of Gsa was unaffected by the pres-
ence of agonist. Such data define the interaction of
the agonist occupied m-opioid receptor with ‘‘G -i
 .type’’ G proteins Fig. 3 . To explore in further detail
 .the molecular identity of the G -protein s activatedi
by the m-opioid receptor in clone m11 membranes,
w32 xwe performed cholera toxin-catalyzed P ADP-ribo-
sylation on such membranes in the presence and
absence of DAMGO and subsequently immunopre-
cipitated these samples with antisera which selec-
tively identify G 2a and G 3a . SDS–PAGE andi i
autoradiography of these immunoprecipitates demon-
strated DAMGO-stimulated incorporation of radioac-
tivity into both G 2a and G 3a . No radioactivelyi i
labelled polypeptide was detected when using non-
immune serum. These results indicate that the m-
opioid receptor has the ability when expressed in
these cells to functionally interact with both G 2ai
and G 3a .i
3.3. Identification of the critical domains in˝ol˝ed in
m-opioid receptor–G protein coupling
To determine which domains of the opioid recep-
tor would be critical to the effective m-opioid recep-
tor–G protein coupling, a series of peptides was used.
The composition and sequence disposition of the
synthetic peptides from the cytoplasmic regions of
the cloned murine d-opioid receptor are indicated in
Fig. 1. These sequences were selected to represent
elements of the NH - and COOH-termini of the2
second and third intracellular loops of opioid recep-
tors as well as a conserved region of the proximal
w32 x Fig. 3. DAMGO-induced cholera toxin-catalyzed P ADP-ribosylation and subsequent immunoprecipitation of G a . Membranes 50i
. w32 x  .  .mg from m11 cells were incubated with P NAD and thiol-activated cholera-toxin in the presence q or absence y of 10 mM
 .  .DAMGO part 1 as described in Section 2. Subsequently, samples were immunoprecipitated using either preimmune serum part 2 or
 .  . w x  .selective antisera against G 2a part 3 and G 3a part 4 9 . Samples were resolved by SDSrPAGE 10% acrylamide exposed to ai i
phosphor storage plate and developed.
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w xC-terminal tail 1–3 . Some of the peptides contain
residues of the predicted transmembrane domains
thought to be crucial for membrane interaction and
the formation of a biologically active conformation
w x16 .
To determine whether these peptides would be
able to modify opioid binding affinity at the m-opioid
receptor of clone m11 cells, preincubations of the
membranes with each of the peptides were performed
and the subsequent specific binding of the opioid
agonist DAMGO was examined. As demonstrated in
 .Fig. 4, only 30 " 6% n s 5 of the specific
w3 x  .H DAMGO 4 nM binding was observed when
membranes of clone m11 were preincubated in the
presence of the poorly hydrolyzed guanine nucleotide
 .  .analog Gpp NH p 100 mM which functionally un-
couples receptors from their associated G proteins.
Similarly, preincubations of these membranes with
the peptides corresponding to either the proximal end
 .of the third cytoplasmic loop i3.1 or the COOH-
 .terminal tail i4 of the opioid receptor reduced
w3 x  . wH DAMGO 4 nM binding i3.1s55"8% and
xi4s35"8% . In contrast, a peptide derived from
 .the distal end of the third intracellular loop i3.3 was
unable to produce any significant reduction in the
w3 xspecific H DAMGO binding. Moreover, peptides
derived from the second intracellular loop or the
w3 xFig. 4. Effect of peptides on specific H DAMGO binding to
clone m11 membranes. Clone m11 cell membranes were preincu-
 .  .bated with buffer, Gpp NH p 100 mM , and the peptides de-
scribed in Fig. 1 or combinations of the peptides, for 60 min at
w3 x  .308C before the specific H DAMGO 4 nM binding, which was
performed as described in Section 2. Non-specific binding was
defined in the presence of 10 mM naloxone. Results are pooled
from three or more individual experiments and represent the
mean " standard error.
intermediate portion of the third cytoplasmic loop
were also without any significant effect. A combina-
tion of the effective peptides, i3.1 and i4 at high
 . w3 xconcentrations 100 mM, each reduced H DAMGO
binding to nearly 20"5% of the initial value Fig.
.4 .
To further evaluate the significance of the inhibi-
tion in binding produced by the peptide i3.1, as a
measure of m-opioid receptor–G protein specificity,
we analyzed its ability to induce an alteration in the
w3 xmeasured K value for H DAMGO binding. Satu-d
w3 xration analysis of the specific H DAMGO binding
to membranes from clone m11 cells yielded linear
plots, reflecting an apparent single class of high
affinity m-opioid receptor binding sites K value ofd
0.85"0.1 nM, B value of 660"50 fmolrmg ofmax
.membrane protein . When similar assays were per-
 .formed either in the presence of Gpp NH p or pep-
tide i3.1, Scatchard analysis indicated a reduction in
w3 xthe affinity of H DAMGO binding as well as an
apparent reduction in the total number of detectable
sites, indicating that peptide i3.1 was effective in
converting the m-opioid receptor to a low affinity
w  .state. Gpp NH p: B 175"65 fmolrmg, K 5.1max d
"1.3 nM, peptide i3.1: K 2.5"0.8 nM, B 210d max
w3 x"20 fmolrmg of membrane protein for H DAMGO
x  .binding data not shown .
As some of the peptides were apparently able to
block the association of m-opioid receptor with G
proteins, we assessed the influence of these peptides
on functional interactions between receptor and G
 .protein s by examining the ability of all the peptides
to modulate DAMGO stimulation of high affinity
w35 xGTPase activity and specific S GTPgS binding.
Fig. 5 summarizes the effect of the various peptides
on DAMGO stimulated GTPase activity in clone m11
cell membranes. We consistently observed that 10 mM
DAMGO produced 60–80% stimulation of the high
affinity GTPase activity. Treatment of clone m11
membranes with peptides i3.1 and i3.3 which corre-
spond to the NH - and COOH-terminal domains of2
the third intracellular loop, significantly reduced the
DAMGO-stimulated high affinity GTPase, without
significantly affecting the basal GTPase levels data
.not shown . In contrast, peptides i3.2, generated from
an intermediate portion of the third intracellular loop;
the peptide corresponding to the carboxyl-terminal
tail i4; as well as peptides i2.1 and i2.2 which were
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Fig. 5. The effect of peptides on DAMGO-stimulated high affin-
ity GTPase activity in membranes from Rat-1 fibroblasts express-
 .ing the m-opioid receptor. Membranes 5mg of clone m11 cells
were preincubated with either buffer or the various peptides
 .100 mM described in Fig. 1 for 60 min at 308C as described in
w 32 xSection 2. Following the preincubation period, both g- P GTP
 .and DAMGO 10 mM were added and samples were incubated
at 308C for a further 20 min. Basal high affinity GTPase activity
was 10.5"3 pmolrminrmg and the presence of 10 mM DAMGO
stimulated the activity to 18"3pmolrminrmg. Low affinity
GTPase activity was determined by the addition of 100 mM GTP.
Basal GTPase activity was unaffected by the presence of the
peptides. Results are expressed as mean " standard error from
three independent experiments performed in triplicate. ) p-0.05
compared with the corresponding DAMGO-stimulated high affin-
 .ity GTPase activity in the absence of peptide Student’s t-test .
from the second intracellular loop, failed to alter
DAMGO-stimulated high affinity GTPase activity
 .Fig. 5 .
To provide additional evidence for the possible
significance of these regions in the interactions of the
 .m-opioid receptor with cellular G protein s , we ex-
amined the ability of all of the peptides to modulate
w35 xagonist stimulation of specific S GTPgS binding in
clone m11 cell membranes. The addition of 10 mM
GDP was required to observe a clear stimulation of
w35 x w xbasal S GTPgS binding by DAMGO 19,22 . As
shown in Table 1, 10 mM DAMGO produced a con-
 . w35 xsistent stimulation 150% of S GTPgS binding
that was significantly reduced by peptides i3.1 and
i2.1. In contrast, peptide i3.3 was unable to produce
w35 xany reduction in S GTPgS binding. Similar prein-
cubations of the m11 cell membranes with the peptide
i4 failed to alter agonist-mediated stimulation of
w35 xS GTPgS binding. However, when preincubation
of the m11 cell membranes was performed with either
peptides i2.2 or peptide i3.2, both peptides were
Table 1
w35 xDAMGO-stimulated S GTPgS binding to membranes of m11-
cells. The effect of opioid receptor-derived peptides
35w xPeptide % DAMGO-stimulated S GTPgS binding
y 146"4
i2.1 88"3
i2.2 128"4
i3.1 100"5
i3.2 141"3
i3.3 140"3
i4 136"5
 .The ability of DAMGO 10 mM to stimulate the rate of guanine
nucleotide exchange in membranes prepared from clone m11
 .cells was measured. Membranes 15mg were preincubated in the
 .presence or absence of peptides i2.1, i2.2, i3.1, i3.2, i3.3, i4
with 3 mM MgCl as described in Section 2 before binding at2
308C for 60 min. The membranes were then incubated at 48C for
w35 x60 min with 50 nCi S GTPgS in the presence or absence of
w35 x10 mM DAMGO. Basal S GTPgS binding was 148"
4 fmolrmg. Data are presented as DAMGO-stimulated
w35 xS GTPgS binding in mean " standard error values from four
experiments.
unable to produce any alteration in the DAMGO-
w35 xstimulated binding of S GTPgS to G proteins.
Concentration-response curve for the peptide i3.1 on
Table 2
w32 xDAMGO-stimulation of cholera toxin-catalyzed P ADP-ribo-
sylation of a 40 kDa polypeptide in membranes of clone m11 cells
is blocked by peptides i3.1 and i3.3
Peptide % DAMGO stimulated cholera
32w xtoxin-catalyzed P ADP-ribosylation
Control 340
i2.1 320
i2.2 310
i3.1 160
i3.3 280
w32 xCholera toxin-catalyzed P ADP-ribosylation was performed in
the absence of guanine nucleotides and in the presence of 10 mM
 .DAMGO control or in the presence of 100 mM peptides as
 .described in Section 2, on membranes 50 mg of clone m11 cells.
Samples were precipitated and resolved by SDS–PAGE 10%
. .wrv acrylamide . The gel was dried stained with Coomassie
Blue and exposed to a phosphor storage plate for 40 h. Similar
results were produced with two further experiments. Data are
displayed as % radioactivity incorporated into G a proteins ini
response to DAMGO in the presence or absence of the various
 .peptides 100 mM . 100% is the radioactivity incorporated into
G a proteins in the absence of DAMGO or the peptides basali
.value .
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w35 xagonist-stimulated S GTPgS binding in m11 cell
membranes indicated an IC of 70"5 mM data not50
.shown .
The results of the studies described above sug-
gested that the effective peptides could also interfere
w32 xwith cholera toxin-catalyzed P ADP-ribosylation
of the G proteins. Table 2, demonstrates the in-
hibitory effects of peptides i3.1 and i3.3 upon cholera
w32 xtoxin-catalyzed P ADP-ribosylation of the 40 kDa
 .polypeptide s in membranes of m11 cells. Peptide
 . w32 xi3.1 100 mM , inhibited P ADP-ribosylation of
G a by 50%, whereas peptide i3.3, inhibitedi
w32 xP ADP-ribosylation of Gia by 30%. In contrast,
the peptides derived from the second intracellular
loop were without any significant effect.
4. Discussion
Assessments of the specificity of interactions be-
tween opioid receptors and G proteins have indicated
the potential of these receptors to activate multiple G
proteins. However there is little information about the
relative selectivity of interactions of these receptors
with various G proteins in membranes or in whole
cells. Activated receptors display a high affinity bind-
ing site for heterotrimeric G proteins which, depend-
ing on the receptor type, appears to consist of one or
w xmore of cytoplasmic regions of the receptor 12 .
However, the lack of sequence identity in the primary
structure of receptors that are known to interact with
 .the same classes of G protein s has not allowed the
prediction of a consensus sequence. At least four
major regions of GPCRs have been shown to con-
tribute to G protein interactions, the N- and C-
terminus of the third intracellular loop, the second
intracellular loop and part of the C-terminal tail
w x12,13 .
The question of how specific interactions of opioid
receptors with G proteins are generated is of particu-
lar interest, since opioid receptors in the central
nervous system are able to inhibit adenylate cyclase
and regulate a variety of ion channels in a G protein
w xdependent manner 4,7,8,25 . Although ample evi-
dence exists demonstrating the interaction of opioid
receptors with multiple G proteins, a number of
studies have reported differences in the receptor–G
protein coupling specificity between opioid receptor
types. By combining photoaffinity labelling of recep-
w 32 xtor activated G proteins with a- P GTP-azidoani-
w xlide, Laugwitz et al. 8 were able to detect differ-
ences in coupling to pertussis toxin-sensitive G pro-
teins of the m- and d-opioid receptors in membranes
of SH-SY5Y cells. Recent elegant studies using simi-
lar techniques have reported the interaction of the
m-opioid receptor with various G proteins following
w xexpression in CHO cells 26 . Such observations,
although demonstrating that the m-opioid receptor
interacted effectively with multiple Ga subunits did
not define, as reported herein, the significance of
certain domains of the primary structure of the m-
opioid receptor that might be critical for these inter-
actions. To answer these questions we have used a
Rat-1 fibroblast cell line which was transfected to
express stably the rat m-opioid receptor.
A widely used approach to assess regions involved
in receptor–G protein interaction has been the use of
specific receptor peptides based on the primary se-
quence of the receptor. This approach has been suc-
cessfully used to examine possible contact regions for
a range of receptors including both a- and b-adrenor-
w x w xeceptors 17,27 , rhodopsin 18,28 the dopamine D2
w x w xreceptor 29 and the N-formyl-peptide receptor 30 .
Using such a peptide approach we have recently been
able to identify contact sites of the d-opioid receptor
w xfor G like G proteins 19 . The peptides used, repre-i
sented segments of the d-opioid receptor correspond-
ing to the proximal and distal elements of the second
and third cytoplasmic loops and a conserved jux-
tamembraneous region of the carboxyl-terminal tail
w x19 . Alignment of the amino acid sequences of the
d-opioid receptor with the m-opioid receptor reveals
high sequence identity in those regions with the
exception of three amino acids in the amino terminal
region of the third intracellular loop, two amino acids
of the carboxyl-terminal region of the second intra-
cellular loop and replacement of a glutamine and
leucine to glutamate and phenylalanine respectively
in the carboxyl-terminal region of the m-opioid recep-
 .tor Fig. 1 . Such similarity suggests that the m- and
d-opioid receptors are likely to interact with a similar
subset of G proteins. We thus tested the ability of the
peptides noted above in a number of different assays
in membranes of cells transfected to express stably
the m-opioid receptor.
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The pharmacological characterization of the recep-
tor in a clone designated m11, indicated the presence
of some 1600 fmolesrmg protein of specific
w3 xH DAMGO binding with a K value similar to thatd
observed in mammalian brain membranes. This ex-
pressed receptor had the ability to functionally inter-
act with the G protein population present in Rat-1
fibroblasts as demonstrated by the ability of DAMGO
to stimulate high affinity GTPase activity in a dose
  ..dependent manner Fig. 2 B . In a number of studies
the ability of agonist to promote CT-catalyzed
w32 xP ADP-ribosylation to define pertussis toxin sensi-
tive G proteins which interact with receptors has been
widely used. This reaction occurs effectively in the
absence of guanine nucleotides. In membranes of
m11 cells in the absence of receptor ligand, in addi-
w32 xtion to the anticipated P ADP-ribosylation of the
long and short isoforms of Gsa , cholera toxin was
w32 xable to catalyze the P ADP-ribosylation of a 40 kDa
 .G a Fig. 3 . This labelling was enhanced byi
DAMGO. Moreover, selective immunoprecipitation
with antisera which recognise G 2a and G 3ai i
demonstrated effective activation of both of these G
proteins by the m-opioid receptor in clone m11 cells.
These results indicated that the m-opioid receptor has
the ability to functionally interact with both G 2ai
and G 3a following expression in Rat-1 fibroblastsi
 .Fig. 3 .
To test whether the peptides described in Fig. 1
could interfere with receptor–G protein interactions
we measured initially the ability of these peptides to
modify ligand binding to the m-opioid receptor in
membranes of clone m11. Only the peptides corre-
sponding to the N-terminal region of the third intra-
 .  .cellular loop i3.1 and the C-terminal tail i4 pro-
duced a significant inhibition of the specific
w3 xH DAMGO binding. Combinations of two or more
peptides corresponding to different sites of the recep-
tor might be expected to amplify the effect either
additively or synergistically. Indeed, co-application
of the effective peptides i3.1 and i4 almost com-
pletely abolished detectable agonist binding, indicat-
w3 xing an additive effect. Specific H DAMGO binding
to the m-opioid receptor was not inhibited by peptide
i3.3, which in concert with the effects of this peptide
on agonist stimulation of GTPase activity suggests
that peptide i3.3 binds the G protein in such a way
that is not able by itself to influence high affinity
opioid receptor–G protein coupling in m11 mem-
branes.
We additionally examined whether these peptides
could either interfere or mimic m-opioid receptor–G
protein interactions by measuring their ability to
modify agonist-stimulated high affinity GTPase activ-
ity. Only the peptides corresponding to sections of
 .the third intracellular loop i3.1 and i3.3 could inter-
fere with functional m-opioid receptor activation of
 .the G protein s without directly activating the G
protein population. None of the peptides from the
second intracellular loop, the intermediate portion of
the third loop and the carboxyl-terminal tail had any
effect on basal or the agonist-stimulated high affinity
GTPase activity. Peptides i3.1 and i3.3 also had an
inhibitory effect upon cholera toxin-catalyzed
w32 xP ADP-ribosylation of G a . Supplementary studiesi
w35 xwith DAMGO-stimulation of S GTPgS binding in-
dicated that the amino terminal region of the third
 .intracellular loop i3.1 could also modify this nu-
cleotide exchange. In contrast, the peptide derived
 .from the carboxyl-terminal tail i4 , although it re-
duces high affinity agonist binding, in a G protein-de-
pendent manner, it does not affect activation of the G
protein as observed in agonist-stimulated GTPase
w35 xactivity and S GTPgS binding. The most likely
mechanism for the effect of this peptide is that it acts
on different sites on the G protein. Peptide i2.1 had
w35 xan inhibitory effect on S GTPgS binding. The
reasons for this apparent discrepant result are unclear
and may be due to a non-specific effect since even at
higher concentrations of peptide i2.1, we could not
modify either GTPase activity or agonist-driven
w32 xcholera toxin-catalyzed P ADP-ribosylation of the
 .G proteins in m11 membranes data not shown .
Of the six synthetic peptides covering the intra-
cellular parts of the receptor used in this study, three
showed a blocking effect, with micromolar range
concentrations, either in agonist binding or G protein
activation. The three effective peptides appear to
work through different mechanisms and therefore fall
 .into three categories: i peptide i3.1, which both
interferes with the coupling of the m-opioid receptor
 .with the G protein s and also affects activation as
 .indicated in agonist binding and G protein assays, ii
peptide i3.3, which does not inhibit agonist binding
but affects only agonist mediated GTPase activity
 .and finally, iii peptide i4 which affects agonist
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binding but is not involved in G protein activation.
These observations indicate that there are different
determinants of receptor–G protein coupling and di-
rect G protein activation. Moreover the role of bg
subunits should not be overlooked. It is therefore
likely, given the inability of the peptide i4 to alter G
protein activation, that this peptide interacts to differ-
ent sites on the a and bg subunits of the G protein
w x31 . The second intracellular loop and the intermedi-
ate portion of the third intracellular loop do not
appear to be involved as discrete sites of G protein
interaction. These data suggest that the opioid recep-
tors contain at least three regions which are important
 .for association with the G protein s ; two parts of the
third intracellular loop and a membrane proximal
portion of the carboxyl-terminal tail. However, the
most interesting finding in this study is that these
same peptides exert similar effects for both m- and
d-opioid receptors. These observations indicate that
the structural determinants responsible for the interac-
tion of opioid signal transduction mediated by G
proteins are probably located in the same domains for
both receptor types despite the differences observed
in their G protein coupling specificity.
Several mutagenesis and peptide studies indicate
that the third intracellular loop of GPCR’s might act
in concert with other domains to determine the effi-
ciency and the selectivity of receptor–G protein cou-
w xpling 12–18 . Mutagenesis studies with rhodopsin
w x w x32 and adrenergic receptors 33 have also sug-
gested that the carboxyl-terminal tail plays a crucial
role in maintaining productive G protein coupling. In
addition, the second intracellular loop has also been
reported to be essential for neutrophil-N-formyl pep-
w xtide receptor–G protein interaction 30,34 . Elegant
w xwork by Konig et al., 18 using peptides derived
from the second and third intracellular loops as well
as the C-terminal tail of rhodopsin indicate that all
regions interact synergistically with transducin. All of
these observations suggest the existence of multiple
intracellular domains that might form a three dimen-
sional binding site of the receptor with its G protein.
The fact that the small amino acid differences be-
tween m- and d-opioid receptors did not influence the
character or the significance of these regions imply
that there are discrete amino acid sequences in the
third intracellular loop andror the C-terminal tail
which might be playing a critical role in determining
the selectivity of receptor–G protein interaction.
Moreover it should be noted that proper receptorrG
protein coupling involves not only several receptor
domains but also various sites of the Ga or Gbg
w xsubunits 28,31,35 . It is therefore likely that specific
interactions besides the one described herein can
modulate receptor–G protein activation and increase
the specificity of receptor–G protein coupling. The
development of both functional and structural maps
of these sites will be important to the understanding
of the mechanisms of G protein activation and the
design of new agents which modulate signal trans-
duction mechanisms. The receptor–G protein contact
sites identified in this study should serve as a useful
starting point for the delineation of structural models
of the receptor–G protein interface.
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